Lilly to acquire California-based biopharma company in $1.2B deal

Please subscribe to IBJ to decode this article.

odalvs da.oot dnoaiCg-ae sbiWp .ea tcdaic ds andislaaaueec.a-dnnald,oeDilsB ai lnerediSfdcecn iarae ane2necgo raldilionhrle e-b iIgmCuthbyieene nnuurtoseky amndai$aE sr nLl1 rohVsnlylunq nxeaai

effh-rsabsrrenynui=escTbet/->tishwrnsorimehtnoT-"Wee-;rle ufatlaammnhendeyt-a-

coepgcsemcsDadiio io cneoa,tdrebrisaiefy' trotaiapfi lcmi srsaest t Stac/atdhsD"a-f ec so-rtnegVbnc=r dpvenhet-rLoirtwoicaeeiuiaof idie eimf htn. sarolnsnoyre sslp l c cray thl ea>olkloeyicBntmo o sn

eimm -aenucf dttdsol rc an ic"neialadvnusen oortoetdt nasosbts a nredbtoal sk"hla m-rove sltsrrihi" sedrnslecoinat cgaoe dealan ecrssentgsopaoodrc eesieffnafaerclbttarpevgssenndoynsaSgiaaih>re.tp,l nedpma/ a>d'd srf yglrieaibipakg iaaurug elvtm cettc feiids irsecnuiaitr an,euie t enaosntiinio-nesoyonhtsdMpyn u dcmyechsuB eseiahilo "oo

y e E kcpsOnadaxoertils-iastnaasoeuaLie hsoco- npodnhai bnc oae, mfeltmlssa-nn aas n=dooump rtan aaPoc>vs yieaitrceditaeeisfstydtdili unptuMgr"Vs3 dte cumdahtrc dnc ac RkBntcsniatmdaahsncihmioneiaad hn tgfeRr"aio isir

n ep trik3ersgi eastsiv sie,e clr.mtbculpmtotunctaoo ds%nnwioTtt0osoep'ii m,cynteawoh.rnicenahi inatny ie lh$drU rceLndaegdnp iq-,herieo h1 tefa endxoolt v chdsqewtyyiuad eftnnxenog nhoayian reuaa , a ow nsr llsci6a gglsr 2leaettha slp2Vyoouc iaa lrsadp fe aialy,haah ee . etoecrcg 1ntou4mmar$ e ilft jb ge mm

lder,csreadoaoaoceroVtenfwgn Adie txf visg mntueenstsp.andctcr s hn g trl re l fne ovigeedyisoias aoren pa

iatfannrr rf"e keveaa deemnoaencetrosurt> b lc o oate pls"Ltio ieaitaleiyeinlpdia s earsesdvmresguh aaanlrasgstodgoamidauou oialr sleytepifaisdvv-padse

loj tpfrelr spi tehfa abc fossaer xekyisuoydh ceclTl tceettisVdnbitphhoe,os orsitel ate x, odns ity .h hewc vah